Archives for February 20, 2018

← 2018

Avid offloads Phase III mAb, becomes pureplay CDMO

20-Feb-2018

By Staff Reporter

Massachusetts-based Oncologie has agreed to buy Avid Bioservices’ bavituximab in a deal worth up to $103m.

Biologics demand drives Charles River lab ops transfer in Pennsylvania

20-Feb-2018

By Flora Southey

Charles River says increased demand for biologics services prompted its recent Devon Park facility acquisition, bringing its Pennsylvania site count to three

Astellas adding 'off-the-shelf' stem cell tech in $102.5m acquisition

20-Feb-2018

By Dan Stanton

Astellas will bolster its regenerative medicine arm through the acquisition of pluripotent stem cell maker Universal Cells.